PTC Therapeutics (PTCT) Competitors

PTC Therapeutics (NASDAQ:PTCT) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations.

Which has more volatility & risk, PTCT or SMMT?

PTC Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -0.46, indicating that its stock price is 146% less volatile than the S&P 500.

Does the MarketBeat Community believe in PTCT or SMMT?

PTC Therapeutics received 261 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 61.92% of users gave PTC Therapeutics an outperform vote while only 58.44% of users gave Summit Therapeutics an outperform vote.

Company	Underperform	Outperform
PTC Therapeutics	Outperform Votes 569 61.92%	Underperform Votes 350 38.08%
Summit Therapeutics	Outperform Votes 308 58.44%	Underperform Votes 219 41.56%

Which has higher valuation and earnings, PTCT or SMMT?

Summit Therapeutics has lower revenue, but higher earnings than PTC Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$806.78M	4.38	-$626.60M	-$4.73	-9.48
Summit Therapeutics	$700K	26,747.22	-$614.93M	-$0.31	-81.87

Do insiders & institutionals have more ownership in PTCT or SMMT?

4.6% of Summit Therapeutics shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by insiders. Comparatively, 88.3% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Is PTCT or SMMT more profitable?

Summit Therapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -50.32%. PTC Therapeutics' return on equity of 0.00% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-50.32%	N/A	-16.44%
Summit Therapeutics	N/A	-85.42%	-52.66%

Do analysts recommend PTCT or SMMT?

PTC Therapeutics currently has a consensus price target of $63.77, indicating a potential upside of 42.27%. Summit Therapeutics has a consensus price target of $35.40, indicating a potential upside of 39.47%. Given PTC Therapeutics' higher probable upside, research analysts plainly believe PTC Therapeutics is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.53
Summit Therapeutics	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to PTCT or SMMT?

In the previous week, Summit Therapeutics had 3 more articles in the media than PTC Therapeutics. MarketBeat recorded 13 mentions for Summit Therapeutics and 10 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 1.18 beat Summit Therapeutics' score of 0.98 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PTC Therapeutics beats Summit Therapeutics on 10 of the 19 factors compared between the two stocks.